<h3>Aim</h3> Allogenic hematopoietic cell transplantation (AlloHCT) is currently a curative cellular therapy approach in hematological malignancies of adults. Donor availability and eligibility of the recipient have been always the major steps on moving forward in alloHCT. Establishing a national registry is difficult task and present registries as partners of WMDA are serving worldwide on international platform. TURKOK is a new donor registry, established by Turkish Ministry of Health in 2015. The current grounds in donor availability/unrelated search is currently questioned by the rise in haplotype matched AlloHCT era. As a single active center since 2010, having performed more than 600 alloHCT, we analyzed the impact of TURKOK on our transplant kinetics and registry based outcome, hypothesizing faster kinetics for logistics and better survival using own citizens, who may have less disparity on HLA immunogenetics basis. <h3>Material and Methods</h3> One hundred and seventeen adult (17-72 years) patients who underwent AlloHCT using matched unrelated donors (MUD) at Florence Nightingale Hospital Hematopoietic Stem Cell Transplantation Center between 2015 and 2019 were included in this study. Medical records of patients were reviewed retrospectively. Transplantation was performed in cases with high or very high DRI. The analysis have been performed on intent to treat basis, having AlloHCT as landmark. Our alloHCT activity using MUD started in 2012, among 127 AlloHCT performed MUD were provided from German BM Registry (DKMS) (n=80), TURKOK (n=38), from other national registries (non-DKMS) (n=9). <h3>Results</h3> The donors differ significantly only on CMV seropositivity, in TURKOK more than 90%, whereas in others less than 55% . Matching rate (%) 9/10-10/10 was nearly the same for DKMS, TURKOK and non-DKMS, 60-40, 66.7-33.3 and 55.3-44.7, respectively. In 2015 only 20% of the MUD AlloHCT were facilitated by TURKOK in our center whereas in 2018 more than 55%. Mean duration (SD1) from start of the donor search to infusion of HSC for DKMS, TURKOK and non-DKMS was 176.2 (142.3), 92 days (40.4) and 123 (63.4), respectively. The overall survival analysis at 2 years showed no statistical difference on log-rank analysis (p=0.24) (Figure 1). <h3>Conclusion</h3> Turkish national donor registry, TURKOK is serving faster as expected due to native donor candidates and facilitated logistics. The CMV donor positivity is clearly different in TURKOK, any impact on transplant outcome is still not clear. The HLA disparity is nearly the same on all three groups and survival analysis did not show any impact of national or international donor registry on transplant outcome. We concluded that TURKOK is serving faster and with similar impact on our alternative donor AlloHCT activity in comparison with international registries.